ProCE Banner Activity

Phase I Trial of Selinexor With Ruxolitinib in Previously Untreated Myelofibrosis

Slideset Download
Conference Coverage

Preliminary data through 24 weeks suggest encouraging efficacy with selinexor plus ruxolitinib based on improvements in spleen volume, total symptom score, and hemoglobin stabilization.

Released: December 17, 2022

Expiration: December 16, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen